BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 28400167)

  • 1. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.
    Karnes RJ; Choeurng V; Ross AE; Schaeffer EM; Klein EA; Freedland SJ; Erho N; Yousefi K; Takhar M; Davicioni E; Cooperberg MR; Trock BJ
    Eur Urol; 2018 Feb; 73(2):168-175. PubMed ID: 28400167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
    Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
    Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
    Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
    Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
    Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
    Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting.
    Howard LE; Zhang J; Fishbane N; Hoedt AM; Klaassen Z; Spratt DE; Vidal AC; Lin D; Hitchins MP; You S; Freeman MR; Yamoah K; Davicioni E; Freedland SJ
    Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):419-428. PubMed ID: 31844180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
    Nguyen PL; Haddad Z; Ross AE; Martin NE; Deheshi S; Lam LLC; Chelliserry J; Tosoian JJ; Lotan TL; Spratt DE; Stoyanova RS; Punnen S; Ong K; Buerki C; Aranes M; Kolisnik T; Margrave J; Yousefi K; Choeurng V; Davicioni E; Trock BJ; Kane CJ; Pollack A; Davis JW; Feng FY; Klein EA
    Eur Urol; 2017 Nov; 72(5):845-852. PubMed ID: 28528811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy.
    Spratt DE; Dai DLY; Den RB; Troncoso P; Yousefi K; Ross AE; Schaeffer EM; Haddad Z; Davicioni E; Mehra R; Morgan TM; Rayford W; Abdollah F; Trabulsi E; Achim M; Tapia ELN; Guerrero M; Karnes RJ; Dicker AP; Hurwitz MA; Nguyen PL; Feng FFY; Freedland SJ; Davis JW
    Eur Urol; 2018 Jul; 74(1):107-114. PubMed ID: 29233664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy.
    Freedland SJ; Choeurng V; Howard L; De Hoedt A; du Plessis M; Yousefi K; Lam LL; Buerki C; Ra S; Robbins B; Trabulsi EJ; Shah NL; Abdollah F; Feng FY; Davicioni E; Dicker AP; Karnes RJ; Den RB
    Eur Urol; 2016 Oct; 70(4):588-596. PubMed ID: 26806658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy.
    Punnen S; Freedland SJ; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Carroll PR; Cooperberg MR
    Eur Urol; 2014 Jun; 65(6):1171-7. PubMed ID: 23587869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
    Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
    Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
    Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
    Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men.
    Ross AE; Yousefi K; Davicioni E; Ghadessi M; Johnson MH; Sundi D; Tosoian JJ; Han M; Humphreys EB; Partin AW; Walsh PC; Trock BJ; Schaeffer EM
    Eur Urol; 2016 Mar; 69(3):496-504. PubMed ID: 25922274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.
    Karnes RJ; Bergstralh EJ; Davicioni E; Ghadessi M; Buerki C; Mitra AP; Crisan A; Erho N; Vergara IA; Lam LL; Carlson R; Thompson DJ; Haddad Z; Zimmermann B; Sierocinski T; Triche TJ; Kollmeyer T; Ballman KV; Black PC; Klee GG; Jenkins RB
    J Urol; 2013 Dec; 190(6):2047-53. PubMed ID: 23770138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    Eur Urol; 2017 Jun; 71(6):907-912. PubMed ID: 27876305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of a Genomic Classifier for Predicting Post-Prostatectomy Recurrence in a Community Based Health Care Setting.
    Glass AG; Leo MC; Haddad Z; Yousefi K; du Plessis M; Chen C; Choeurng V; Abdollah F; Robbins B; Ra S; Richert-Boe KE; Buerki C; Pearson K; Davicioni E; Weinmann S
    J Urol; 2016 Jun; 195(6):1748-53. PubMed ID: 26626216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier.
    Tosoian JJ; Birer SR; Jeffrey Karnes R; Zhang J; Davicioni E; Klein EE; Freedland SJ; Weinmann S; Trock BJ; Dess RT; Zhao SG; Jackson WC; Yamoah K; Dal Pra A; Mahal BA; Morgan TM; Mehra R; Kaffenberger S; Salami SS; Kane C; Pollack A; Den RB; Berlin A; Schaeffer EM; Nguyen PL; Feng FY; Spratt DE
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):646-653. PubMed ID: 32231245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of the prognostic value of a three-gene signature and clinical parameters-based risk score in prostate cancer patients.
    Saemundsson A; Xu LD; Meisgen F; Cao R; Ahlgren G
    Prostate; 2023 Sep; 83(12):1133-1140. PubMed ID: 36988135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy.
    Den RB; Yousefi K; Trabulsi EJ; Abdollah F; Choeurng V; Feng FY; Dicker AP; Lallas CD; Gomella LG; Davicioni E; Karnes RJ
    J Clin Oncol; 2015 Mar; 33(8):944-51. PubMed ID: 25667284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis.
    Tosco L; Laenen A; Briganti A; Gontero P; Karnes RJ; Bastian PJ; Chlosta P; Claessens F; Chun FK; Everaerts W; Gratzke C; Albersen M; Graefen M; Kneitz B; Marchioro G; Salas RS; Tombal B; Van den Broeck T; Van Der Poel H; Walz J; De Meerleer G; Bossi A; Haustermans K; Van Poppel H; Spahn M; Joniau S;
    Eur Urol Focus; 2018 Apr; 4(3):369-375. PubMed ID: 28753838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.